Oncology - Novartis
WEBOncology. Combining the power of science and empathy to unravel the inner workings of cancer and develop innovative therapies that restore hope to those with cancer and their loved ones.
Products - Novartis
WEBDiscover the diverse and innovative Novartis Global Product Portfolio and find information about each pharmaceutical treatment.
Novartis patient support for oncology
WEBNovartis Patient Support is a comprehensive program designed to help you start, stay, and save on treatment. You can sign up once your health care provider prescribes you or your loved one a Novartis medication. You’ll have access to a team who can help support you.
FDA approves ribociclib with an aromatase inhibitor and ...
WEB5 days ago · On September 17, 2024, the FDA approved ribociclib (Kisqali, Novartis Pharmaceuticals Corporation) with an aromatase inhibitor and ribociclib and letrozole co-pack (Kisqali Femara Co-Pack ...
Novartis expands Oncology pipeline with in-licensing of
WEBBasel, January 11, 2021 — Novartis has signed a strategic collaboration agreement to in-license tislelizumab from BeiGene, Ltd. in major markets outside of China, accelerating the potential for...
Novartis strengthens immunotherapy pipeline with option,
WEBDec 20, 2021 · Novartis is advancing tislelizumab as a potential bridge to enable synergistic combinations, with the goal of extending survival for more patients through novel combinations across tumors and...
GLEEVEC® (imatinib mesylate) | KIT + GIST & Ph+ CML
WEBNovartis will pay the remaining co-pay, up to $30,000 per calendar year*. Encourage your patients to find out if they are eligible to enroll in the Universal Co-pay Program by visiting Copay.NovartisOncology.com or calling 1-877-577-7756. *Limitations apply.
- Some results have been removed